Muraglitazar

CAS No. 331741-94-7

Muraglitazar( —— )

Catalog No. M33747 CAS No. 331741-94-7

Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 683 Get Quote
10MG 938 Get Quote
25MG 1371 Get Quote
50MG 1822 Get Quote
100MG 2475 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Muraglitazar
  • Note
    Research use only, not for human use.
  • Brief Description
    Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.
  • Description
    Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ(EC50 = 110 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    331741-94-7
  • Formula Weight
    516.54
  • Molecular Formula
    C29H28N2O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(COC1=CC=C(CN(C(OC2=CC=C(OC)C=C2)=O)CC(O)=O)C=C1)C=3N=C(OC3C)C4=CC=CC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195. ?
molnova catalog
related products
  • LJ570

    LJ570 is the first PPARα/γ dual agonist (PPARαPPARγ with EC50s of 1.05 and 0.12 μM respectively.

  • Mifobate

    Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects.

  • Angeloylgomisin H

    Angeloylgomisin H shows moderate cytotoxic activities with IC50 values ranging from 100 to 200 ug/mL against MCF7, HEK293 and CAL27 cell lines.